t(11;14)

MCL Literature Feed

797 papers on mantle cell lymphoma from PubMed. Updated daily.

ADCBCL2iBTKiCAR-TCDK4/6iCNSMRDPI3KiTP53-mutatedbiomarkersbispecificblastoidcase reportchemotherapyconsolidationelderlyepidemiologyfrontlinegenomicsguidelines
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.

Quantifying the survival cost of delayed CAR T-cell reimbursement in Europe shows faster access for MCL patients would translate directly into more lives and life-years saved.

Yan Zhi Tan, Emily Breislin, Matthew Woods et al.·Journal of medical economics·Dec 1, 2026
CAR-Trelapsed/refractoryreal-worldhealth economicsepidemiology
A murine proof-of-concept study of polatuzumab vedotin in combination with venetoclax in experimental therapy of BCL2-positive aggressive lymphomas.
Eva Pokorna, Dmitry Manakov, Kristyna Nozickova et al.·Scientific reports·Jun 8, 2026
In mantle cell lymphoma, whether 18 F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.
Di Wang, Haochen Wu, MengHan Li et al.·Annals of hematology·Jun 5, 2026
Ibrutinib improves overall survival in patients with mantle cell lymphoma.
Peter Sidaway·Nature reviews. Clinical oncology·Jun 3, 2026
Orbital infiltration in relapsed mantle cell lymphoma.
Francisco Calleja-Casado, Jonathan Molina García, Diego Serrano Fernando·Orbit (Amsterdam, Netherlands)·Jun 2, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real-World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T-Cell Era.
Enver Aydilek, Paolo Mazzeo, Justin Hasenkamp et al.·EJHaem·Jun 1, 2026
CAR T-cell therapy-associated central hypothyroidism: a case of a novel onco-endocrine toxicity.
Maria Martinez-Cruz, Lauren Mozingo, Courtney Dominguez et al.·JCEM case reports·Jun 1, 2026
Immune receptor translocation-associated protein 1 and myeloid nuclear differentiation antigen are useful markers for the differential diagnosis of marginal zone lymphoma.
Wen-Wen Zhang, Long-Feng Ke, Chen-Yu Wu et al.·Pathology·Jun 1, 2026
Modern Management of Mantle Cell Lymphoma.
Tobias Tix, Anita Kumar, Toby A Eyre et al.·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·Jun 1, 2026
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.
Alberto J Arribas, Eleonora Cannas, Giulio Sartori et al.·Blood·May 29, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry.
Hyungwoo Cho, Koji Kato, Jason Yongsheng Chan et al.·Blood cancer journal·May 29, 2026
Significant variations in first-line mantle cell lymphoma care-an Australasian Lymphoma and Related Diseases Registry study.
Zoe Loh, Eliza Chung, Cameron Wellard et al.·Leukemia & lymphoma·May 26, 2026
Towards the Definition of a Prognostic Model for Mantle Cell Lymphoma.
Simone Ferrero, Riccardo Francia, Marco Ladetto et al.·Studies in health technology and informatics·May 21, 2026
First BCL-2 Inhibitor Approved for Mantle Cell Lymphoma.
·Cancer discovery·May 21, 2026
"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVL.
Lorenzo Iovino, Mazyar Shadman, Filippo Milano et al.·Blood advances·May 20, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

End of transplantation's reign in mantle cell lymphoma.
Judith Trotman, Janlyn Falconer·Lancet (London, England)·May 16, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Martin Dreyling, Jeanette Doorduijn, Eva Giné et al.·Lancet (London, England)·May 16, 2026
Design, synthesis, and biological evaluation of 2-morpholino-4H-chromen-4-one derivatives as a potent dual PI3K/BRD4 inhibitors.
Krishnaiah Maddeboina, Bharath Yada, Cody C McHale et al.·European journal of medicinal chemistry·May 15, 2026
Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis Following CAR T-Cell Therapy: Results of a Real-World Study.
Inna Shaforostova, Marie-Noelle Kronig, Katja Seipel et al.·Cancers·May 14, 2026
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).
Miguel Bastos-Boente, Alejandro Medina-Herrera, Almudena Navarro-Bailón et al.·British journal of haematology·May 14, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture.
Moinul Haque, Razie Amraei, Krasimira A Rozenova·Hematology reports·May 13, 2026
Population-based survival after mantle cell lymphoma in Norway and Denmark: Limited impact of earlier BTKi access.
Mikkel Runason Simonsen, Marianne B Jerm, Tom B Johannesen et al.·British journal of haematology·May 12, 2026
Proteasome inhibition enhances lysosome-mediated targeted protein degradation.
Ahmed M Elshazly, Nayyerehalsadat Hosseini, Janakiram Vangala et al.·Cell death & disease·May 11, 2026
Cutaneous Involvement by Blastoid Mantle Cell Lymphoma Presenting as Cervical Abscess: A Rare Extranodal Diagnostic Challenge.
Shreya Sharma, Ankita Soni, Manjit Kaur Rana et al.·Journal of cutaneous pathology·May 10, 2026
More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.
Raji E Joseph, Robert G Britton, David Yin-Wei Lin et al.·bioRxiv : the preprint server for biology·May 8, 2026
Get the weekly MCL digest

The 5 most important MCL papers of the week, summarized. Free, no spam, unsubscribe anytime.

Cyclin-Dependent Kinase 5 Contributes to Bruton's Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma.
Alexey Danilov, Sonia Rodriguez-Rodriguez, Dan Vuong et al.·Research square·May 8, 2026
Classic Hodgkin lymphoma with IGH::CCND1 rearrangement: evidence of clonal relation to preceding mantle cell lymphoma.
Ahmed A Ahmed, Saber Tadros·Blood·May 7, 2026
Association Between Progression-Free Survival and Overall Survival in Mantle Cell Lymphoma: A Trial-level Surrogate Endpoint Analysis.
Alexander M Gorzewski, Christina Raker, Victoria A Gill et al.·Clinical lymphoma, myeloma & leukemia·May 5, 2026
Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party?
Andre Costa Meireles, Paloma Martinho Resende, Laura Korin et al.·Clinical lymphoma, myeloma & leukemia·May 4, 2026
An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.
Jonathon B Cohen, Craig A Portell, Mehdi Hamadani et al.·Clinical lymphoma, myeloma & leukemia·May 4, 2026
Page 1 of 27Next →